THOROFARE, N.J., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the "Company" or "ABI"), a leading designer and manufacturer of rapid diagnostic screening and testing products, will hold a conference call on Thursday, November 13, 2014, at 10:30 a.m. Eastern Time to discuss its results for the third quarter and nine months ended September 30, 2014.
Akers Biosciences' Co-Founder and Executive Chairman, Raymond F. Akers, Jr. PhD, and Vice President of Finance, Gary Rauch, will host the call and be available during the question-and-answer session.
To participate in the call, please dial (888)-820-9415 or 1-(913)-312-9330 for international callers, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found via the Company's website at http://ir.akersbiosciences.com/events.cfm, or alternately at http://public.viavid.com/index.php?id=111901. The Conference ID is 7992989.
A replay of the call will be available for two weeks from 1:30 p.m. ET on November 13, 2014, until 11:59 p.m. ET on November 27, 2014. The number for the replay is (877)-870-5176, or 1-(858)-384-5517 for international callers; the passcode for the replay is 7992989. In addition, a recording of the call will be available via the Company's website at http://www.akersbiosciences.com.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.